4 July 2017 - This Cost Recovery Implementation Statement provides information on how the TGA implements cost recovery activities associated with the registration and listing of medicines and inclusion of medical devices, including in vitro diagnostic devices, and biologicals onto the Australian Register of Therapeutic Goods and the ongoing monitoring and surveillance of them.

The TGA's cost recovery arrangements cover the following industry sectors:

• prescription medicines
  
• over the counter medicines
  
• complementary medicines
  
• medical devices, including in-vitro diagnostic (IVD) devices
  
• good manufacturing practices
  
• blood, blood components and biologicals.
  

While some funding is provided by the Government for meeting the cost of scheduling activity, and in the form of an interest equivalency payment against the special account balance (reserves), the bulk of funding is generated through fees and charges charged under cost recovery arrangements.

Read TGA news article